Search clinical trials for: GS-9669 tablets

Total 7136 results

Tasly Pharmaceutical Group Co., Ltd

Completed

Study of Jitongning Tablet to Treat Spondyloarthritis

Spondyloarthritis

China
National Institute of Allergy and Infectious Diseases...

Completed

Combination Therapy for Chronic Hepatitis C Infection

Hepatitis C, Chronic

United States
Gilead Sciences

Completed

Efficacy and Safety of Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection in Participants With Chronic Genotype 1, 2, 3, or 6 HCV Infection

Chronic Hepatitis C

New Zealand
Gilead Sciences

Completed

Ledipasvir/Sofosbuvir Fixed-Dose Combination With Ribavirin or GS-9669 in Subjects With Chronic Genotype 1 HCV Infection

Chronic HCV Infection

United States
Gilead Sciences

Completed

Open-Labeled Study of PSI-7977 and RBV With and Without PEG-IFN in Treatment-Naïve Patients With HCV GT2 or GT3

Chronic Hepatitis C Infection

New Zealand
Gilead Sciences

Completed

A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-6620 in Treatment Naïve Subjects With Chronic Hepatitis C Virus Infection

Hepatitis C, Chronic

United States, Puerto Rico
Gilead Sciences

Completed

Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-9669 in Subjects With Chronic Hepatitis C Virus Infection

Hepatitis C

United States, Puerto Rico
Oslo University Hospital
Göteborg University; Sahlgrenska University Hospital, Sweden

Completed

Pharmaceutical Treatment of Fatigue After Aneurysmal Subarachnoid Hemorrhage

Aneurysmal Subarachnoid Hemorrhage

Norway
Yiling Pharmaceutical Inc.

Completed

A Single-dose Study to Investigate the Tolerance and Pharmacokinetics of Finamine Tablets in China

Parkinson Disease

China
Gilead Sciences

Active, not recruiting

A Study of GS-5423 and GS-2872 in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection

HIV Infections

United States, Australia, Puerto Rico, Canada
Gilead Sciences

Completed

GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection

Chronic Genotype 1a or 1b HCV Infection

United States, Canada, Puerto Rico
Gilead Sciences

Completed

Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection

Hepatitis C, Chronic

United States, Puerto Rico
The National Institutes of Pharmaceutical R&D Co...

Completed

A Safety, Tolerability, and Pharmacokinetic Study of NIP292 in Healthy Normal Subjects

Idiopathic Pulmonary Fibrosis

United States
Sunshine Lake Pharma Co., Ltd.

Completed

The Tolerability , Pharmacokinetics and Pharmacodynamics Study of HEC96719 Tablets in Healthy Adult Subjects

Nonalcoholic Steatohepatitis (NASH)

China
Atridia Pty Ltd.

Completed

A Trial of HRS-7085 Tablet in Healthy Participants With and Without Food Effect.

Inflammatory Bowel Disease

Australia
Harmony Biosciences, LLC

Active, not recruiting

A Phase 2 Study to Evaluate the Safety and Efficacy of Pitolisant in Patients With Prader-Willi Syndrome, Followed by an Open Label Extension

Prader-Willi Syndrome

United States
Lexicon Pharmaceuticals

Completed

A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome

Irritable Bowel Syndrome

United States
Dong Wha Pharmaceutical Co. Ltd.

Completed

The Phase I Clinical Study to Evaluate the Pharmacokinetics of Dw1029M in Healthy Male Volunteer

Diabetic Kidney Disease

Korea, Republic of
University of Chicago

Completed

A Study of Ranolazine Acute Administration and Short Term Administration in Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

United States
Gilead Sciences

Completed

GS 5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) in Chronic Genotype 1 Hepatitis C Virus (HCV) Infection

Hepatitis C, Chronic

United States, Puerto Rico
Rigshospitalet, Denmark

Completed

The Association Between Hyponatremia and Osteoporosis in Patients With Epilepsy.

Hyponatremia | Metabolic Bone Disease

Denmark
Paratek Pharmaceuticals Inc

Active, not recruiting

Oral Omadacycline vs. Placebo in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex (MABc)

Mycobacterium Infections, Nontuberculous | Nontuberculous Mycobacterial Lung Disease | Mycobacterium Abscessus Infection | Nontuberculous Mycobacterial Pulmonary Infection

United States
Gilead Sciences

Completed

Evaluation of the Safety, Tolerability, Pharmacokinetics, and Activity of GS-9450 in Subjects With Chronic HCV

HCV Infection

United States, Netherlands, Germany
Gilead Sciences

Completed

Safety, Tolerability, Pharmacokinetics and Activity of GS-9450 in Adults With Non-Alcoholic Steatohepatitis (NASH)

Nonalcoholic Steatohepatitis

United States, France
Gilead Sciences

Completed

GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C Virus

Hepatitis C, Chronic

United States, Puerto Rico, Australia
Gilead Sciences

Completed

Safety and Effectiveness Study of an Experimental Topical Ointment (GS-9191) for the Treatment of Genital Warts

Genital Warts

United States
Gilead Sciences

Active, not recruiting

Study of HBV Therapeutic Vaccines GS-2829 and GS-6779 in Healthy Participants and Participants With Chronic Hepatitis B

Chronic Hepatitis B

Taiwan, New Zealand
Sinew Pharma Inc.

Completed

Phase I Pharmacokinetic Study of HUYPS-1 in Healthy Volunteers

Nonalcoholic Steatohepatitis

Taiwan
Gilead Sciences
Ono Pharmaceutical Co. Ltd; Galapagos NV

Completed

Study to Assess Safety and Efficacy of Filgotinib, Lanraplenib and Tirabrutinib in Adults With Active Sjogren's Syndrome

Sjogren's Syndrome

United States, Spain, United Kingdom, Poland
Gilead Sciences

Completed

Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor (POLARIS-4)

Hepatitis C Virus Infection

United States, France, United Kingdom, Germany, Canada, Australia, New Zealand, Puerto Rico
Gilead Sciences

Completed

Safety and Efficacy of SOF/VEL/VOX FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis (POLARIS-3)

Hepatitis C Virus Infection

United States, France, United Kingdom, Germany, Australia, Canada, New Zealand, Puerto Rico
Hansoh BioMedical R&D Company

Not yet recruiting

A Study to Find the Best Dose of HS-10384 to Treat Vasomotor Symptoms in Postmenopausal Women

Vasomotor Symptoms

China
Arvid Carlsson Research AB
Gottfries Clinic AB

Completed

Study Evaluating Efficacy and Safety of OSU6162 in the Treatment of Residual Symptoms After Stroke (OSU6162DB003)

Stroke Sequelae

Sweden
Gilead Sciences

Terminated

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of GS-3583 in Participants With Advanced Solid Tumors

Advanced Solid Tumors

United States
Gilead Sciences

Completed

A Phase 1 Study to Evaluate the Pharmacokinetics, Metabolism, and Excretion of GS-5806

RSV Infection

United States
Gesynta Pharma AB
CTC Clinical Trial Consultants AB; RISE Research Institutes of Sweden AB

Completed

A Study in Healthy Subjects to Evaluate Pharmacokinetics and Food Effect After Dosing of GS-248

Pharmacokinetic

Sweden
Otsuka Pharmaceutical Co., Ltd.

Completed

A Clinical Pharmacology Trial of Brexpiprazole Once-weekly (QW) Formulation Administered as Single and Multiple Oral Doses

Schizophrenia

Japan
Valenta Pharm JSC

Recruiting

Safety, Tolerability and Pharmacokinetics of 4-MUST, Tablets, 128 mg (Valenta Pharm JSC) During Single and Multiple Oral Administration in Healthy Volunteers

Cholecystitis

Russian Federation
Gilead Sciences
Galapagos NV

Completed

Study to Evaluate Safety and Efficacy of Filgotinib and Lanraplenib in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)

Cutaneous Lupus Erythematosus

United States, Canada
Gilead Sciences

Completed

Study to Evaluate the Safety and Efficacy of Teropavimab and Zinlirvimab in Combination With Lenacapavir (GS-6207) in Virologically Suppressed Adults With HIV-1 Infection

HIV-1 Infection

United States
Fulcrum Therapeutics

Completed

Relative Bioavailability and Food Effect Study of Losmapimod 15 mg Tablets

Healthy Adult Subjects

United States
Gilead Sciences

Completed

Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral Therapy (POLARIS-2)

Hepatitis C

United States, France, United Kingdom, Germany, Canada, Australia, New Zealand, Puerto Rico
Gilead Sciences

Completed

Efficacy and Safety of Oral Regimens for the Treatment of Chronic HCV Infection (LEPTON)

Chronic Hepatitis C

New Zealand
Gilead Sciences

Completed

Safety And Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination for 12 Weeks in Adults Who Participated in a Prior Gilead-Sponsored HCV Treatment Study

Hepatitis C Virus Infection

Germany, United States, Australia, United Kingdom, Canada, France, New Zealand
Gilead Sciences

Terminated

Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma

Follicular Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Gilead Sciences

Completed

Study of the Effect of GS-6615 in Subjects With LQT-3

Long QT Syndrome

United States
Gilead Sciences

Terminated

A Phase 1 Study to Characterize the Effect of GS-5737 Enhancement of Mucociliary Clearance (MCC) in Healthy Subjects

Chronic Obstructive Pulmonary Disease | Cystic Fibrosis

United States
Overseas Pharmaceuticals, Ltd.
GX pharma technology (beijing) Co., Ltd

Active, not recruiting

An Open Label, Balanced, Randomized, 3×3 Latin Square Design Comparing of Brivaracetam Sustained-release Tablets and Brivaracetam Tablets in the Oral Comparative Pharmacokinetic(PK) Study in Chinese Healthy Adult Subjects Under Fasting Conditions.

Partial Seizure

China
Gilead Sciences

Terminated

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Evixapodlin (Formerly GS-4224) in Participants With Advanced Solid Tumors

Advanced Solid Tumors

United States, New Zealand
Gilead Sciences

Completed

Pharmacokinetics of Voxilaprevir in Adults With Normal Hepatic Function and Moderate or Severe Hepatic Impairment

HCV Infection

United States, Germany, New Zealand

3

Subscribe